Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed

Sunshine Biopharma Inc.

CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.
Consent allows adjustment of Series C Warrants' exercise price or shares in a Share Combination Event.
Consent allows voluntary adjustment of Series C Warrant exercise prices from time to time.
Consent effective 20 days after mailing definitive info statement; part of May 19, 2026 public offering.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sunshine Biopharma Inc. shareholders approved to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants. at the 2026-05-28 meeting.

Outcome: passed
Meeting: 2026-05-28

Exact text from the filing

to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sunshine Biopharma Inc. shareholders approved to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants. at the 2026-05-28 meeting.

Outcome: passed
Meeting: 2026-05-28

Exact text from the filing

to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sunshine Biopharma Inc. shareholders approved to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that at the 2026-05-28 meeting.

Outcome: passed
Meeting: 2026-05-28

Exact text from the filing

to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on May 19, 2026 (the “Offering”).

View on SEC.gov

Browse all shareholder votes →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-004387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.